|
AIDS Research and Human Retroviruses
Short Communication: Association between Tipranavir Plasma Levels and Virological Response in HIV-Infected Patients
To cite this article:
Judit Morello, Pilar Garcia Gascó, Sonia Rodriguez-Novoa, Carmen de Mendoza, Francisco Blanco, Gema Gonzalez-Pardo, Beatriz Sanz, Inmaculada Jimenez-Nacher, Vincent Soriano.
AIDS Research and Human Retroviruses.
March 2008,
24(3): 389-391.
doi:10.1089/aid.2007.0225.
Judit Morello Hospital Carlos III, Madrid 28029, Spain. Pilar Garcia Gascó Hospital Carlos III, Madrid 28029, Spain. Sonia Rodriguez-Novoa Hospital Carlos III, Madrid 28029, Spain. Carmen de Mendoza Hospital Carlos III, Madrid 28029, Spain. Francisco Blanco Hospital Carlos III, Madrid 28029, Spain. Gema Gonzalez-Pardo Hospital Carlos III, Madrid 28029, Spain. Beatriz Sanz Hospital Carlos III, Madrid 28029, Spain. Inmaculada Jimenez-Nacher Hospital Carlos III, Madrid 28029, Spain. Vincent Soriano Hospital Carlos III, Madrid 28029, Spain. ABSTRACT The impact of tipranavir plasma levels (TPV Cmin) on virological response was examined in 36 antiretroviral-experienced HIV-infected individuals. Although TPV Cmin did not predict outcome in patients with less than five or more than eight baseline TPV-associated resistance mutations, TPV Cmin values were greater in responders than in nonresponders with five to seven baseline TPV-associated resistance mutations (38.8 vs. 13.8 g/ml, p = 0.017). Thus, therapeutic drug monitoring might be helpful in ensuring a viral response in this subset of patients. This paper was cited by:Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements I. Jimenez-Nacher, B. Garcia, P. Barreiro, S. Rodriguez-Novoa, J. Morello, J. Gonzalez-Lahoz, C. de Mendoza, V. Soriano Journal of Antimicrobial Chemotherapy. Jul 2008, Vol. 62, No. 4: 816-822 CrossRef |
|
TOC Alert
CiteULike
Delicious
Digg This
Facebook
Newsvine